Aclaris Therapeutics (ACRS) Projected to Post Earnings on Thursday

Aclaris Therapeutics (NASDAQ:ACRS) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Aclaris Therapeutics to post earnings of ($0.15) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Aclaris Therapeutics Price Performance

Shares of ACRS stock opened at $3.25 on Tuesday. Aclaris Therapeutics has a one year low of $1.05 and a one year high of $4.89. The company’s fifty day moving average price is $3.24 and its 200-day moving average price is $2.57. The company has a market capitalization of $352.14 million, a price-to-earnings ratio of -2.36 and a beta of 0.86.

Institutional Investors Weigh In On Aclaris Therapeutics

Hedge funds have recently made changes to their positions in the company. Millennium Management LLC grew its holdings in Aclaris Therapeutics by 111.0% during the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after buying an additional 2,175,101 shares in the last quarter. Kotler Kevin bought a new position in shares of Aclaris Therapeutics during the 4th quarter valued at approximately $5,135,000. Geode Capital Management LLC grew its holdings in shares of Aclaris Therapeutics by 108.4% in the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after purchasing an additional 1,282,042 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in Aclaris Therapeutics in the third quarter worth $2,428,000. Finally, State Street Corp raised its stake in Aclaris Therapeutics by 35.3% during the fourth quarter. State Street Corp now owns 1,506,403 shares of the biotechnology company’s stock valued at $4,534,000 after purchasing an additional 393,257 shares in the last quarter. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ACRS shares. Craig Hallum began coverage on Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research note on Wednesday, January 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.80.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.